Larimar Therapeutics Inc. (LRMR)
NASDAQ: LRMR
· Real-Time Price · USD
4.00
-0.26 (-6.10%)
At close: Aug 15, 2025, 3:59 PM
4.04
1.13%
After-hours: Aug 15, 2025, 06:00 PM EDT
Larimar Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 241K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 74K | 87K | 80K | 81K | 69K | 49K | 54K | 32K | 77K | 81K | 82K | 88K | 88K | 77K | 73K |
Gross Profit | n/a | 241K | -74K | -87K | -80K | -81K | -69K | -49K | -54K | -32K | -77K | -81K | -82K | -88K | -88K | -77K | -73K |
Operating Income | -31.19M | -31.29M | -18.26M | -24.6M | -16.73M | -14.16M | -10.34M | -9.62M | -7.64M | -10.44M | -8.51M | -8.69M | -8.89M | -9.09M | -16.73M | -12.54M | -12.11M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -29.28M | -28.82M | -15.5M | -21.63M | -14.65M | -12.99M | -9.06M | -8.37M | -6.53M | -9.43M | -8.32M | -8.67M | -8.94M | -9.13M | -16.8M | -12.61M | -12.09M |
Net Income | -29.28M | -28.82M | -15.5M | -21.63M | -14.65M | -12.99M | -9.06M | -8.37M | -5.42M | -8.41M | -8.13M | -8.65M | -9M | -9.13M | -16.8M | -12.61M | -12.09M |
Selling & General & Admin | 4.64M | 4.55M | 4.34M | 5.02M | 3.79M | 3.51M | 3.75M | 3.75M | 3.08M | 3.22M | 2.93M | 3.04M | 3.08M | 2.79M | 2.7M | 3.44M | 3.13M |
Research & Development | 26.55M | 26.74M | 13.92M | 19.59M | 12.86M | 10.57M | 6.58M | 5.88M | 4.56M | 7.22M | 5.58M | 5.64M | 5.81M | 6.29M | 14.03M | 9.1M | 8.97M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 20K | -56K | -48K | -75K | -66K | 18K |
Operating Expenses | 31.19M | 31.29M | 18.26M | 24.51M | 16.65M | 14.08M | 10.34M | 9.62M | 7.64M | 10.44M | 8.51M | 8.69M | 8.89M | 9.09M | 16.73M | 12.54M | 12.11M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 56K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | 100K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 31.7M | 18.26M | 24.6M | 16.73M | 14.16M | 10.34M | 9.62M | 7.64M | 10.44M | 8.51M | 8.69M | 8.89M | 9.09M | 16.73M | 12.54M | 12.11M |
Income Tax Expense | n/a | n/a | n/a | n/a | 36.72K | 37.19K | -76K | -46.09K | -1.11M | -1.01M | -193K | -20K | 56K | -88K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 63.96M | 63.81M | 63.81M | 63.8M | 53.55M | 43.91M | 43.9M | 43.9M | 43.9M | 23.99M | 22.23M | 18.34M | 18.34M | 18.34M | 18.29M | 16M | 16M |
Shares Outstanding (Diluted) | 63.96M | 63.81M | 63.81M | 63.8M | 53.55M | 43.91M | 43.9M | 43.9M | 43.9M | 23.99M | 22.23M | 18.34M | 18.34M | 18.34M | 18.29M | 16M | 16M |
EPS (Basic) | -0.46 | -0.47 | -0.24 | -0.34 | -0.27 | -0.3 | -0.21 | -0.19 | -0.12 | -0.35 | -0.37 | -0.47 | -0.49 | -0.5 | -0.92 | -0.79 | -0.76 |
EPS (Diluted) | -0.46 | -0.47 | -0.24 | -0.34 | -0.27 | -0.3 | -0.21 | -0.19 | -0.12 | -0.35 | -0.37 | -0.47 | -0.49 | -0.5 | -0.92 | -0.79 | -0.76 |
EBITDA | -31.1M | -31.22M | -18.26M | -24.51M | -16.65M | -14.08M | -10.26M | -9.54M | -7.56M | -10.36M | -8.44M | -8.61M | -8.8M | -9M | -16.64M | -12.47M | -12.03M |
EBIT | n/a | -28.82M | -18.26M | -24.6M | -16.73M | -14.16M | -10.34M | -9.62M | -7.64M | -10.44M | -8.51M | -8.69M | -8.89M | -9.09M | -16.73M | -12.54M | -12.11M |
Depreciation & Amortization | n/a | 77K | 74K | 87K | 80K | 81K | 69K | 49K | 78K | 32K | 77K | 81K | 82K | 88K | 88K | 77K | 73K |